U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts

Zoetis

Market Cap: US$32.0b

Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.

Insmed

Market Cap: US$24.5b

Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

Summit Therapeutics

Market Cap: US$12.4b

A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

Praxis Precision Medicines

Market Cap: US$9.0b

A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.

Vaxcyte

Market Cap: US$8.8b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

Legend Biotech

Market Cap: US$5.4b

Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.

Oruka Therapeutics

Market Cap: US$5.0b

A clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

Caris Life Sciences

Market Cap: US$4.9b

An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.

Viking Therapeutics

Market Cap: US$4.9b

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Dyne Therapeutics

Market Cap: US$3.9b

A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

Structure Therapeutics

Market Cap: US$3.9b

A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.

Ultragenyx Pharmaceutical

Market Cap: US$3.5b

A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

Kailera Therapeutics

Market Cap: US$2.9b

Operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.

Vera Therapeutics

Market Cap: US$2.9b

A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.

BioCryst Pharmaceuticals

Market Cap: US$2.8b

A biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.

Mineralys Therapeutics

Market Cap: US$2.7b

A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.

SELLAS Life Sciences Group

Market Cap: US$2.7b

A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.

Nektar Therapeutics

Market Cap: US$2.5b

A biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.

Intellia Therapeutics

Market Cap: US$2.5b

Operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

Kodiak Sciences

Market Cap: US$2.3b

A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.

Ocular Therapeutix

Market Cap: US$2.3b

A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.

Viridian Therapeutics

Market Cap: US$2.3b

Engages in discovering, developing, and commercializing treatments for serious and rare diseases.

Zai Lab

Market Cap: US$2.1b

A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.

ADMA Biologics

Market Cap: US$2.1b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Palvella Therapeutics

Market Cap: US$2.1b

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

Generate Biomedicines

Market Cap: US$2.1b

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States.

Taysha Gene Therapies

Market Cap: US$2.1b

A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.

Syndax Pharmaceuticals

Market Cap: US$2.1b

A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Recursion Pharmaceuticals

Market Cap: US$2.0b

A clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.

Nuvation Bio

Market Cap: US$2.0b

A clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.

Precigen

Market Cap: US$2.0b

A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.

Tyra Biosciences

Market Cap: US$1.9b

A clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.

Iovance Biotherapeutics

Market Cap: US$1.9b

A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.

Damora Therapeutics

Market Cap: US$1.8b

A biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.

Bausch Health Companies

Market Cap: US$1.8b

Operates as a diversified specialty pharmaceutical and medical device company.

AtaiBeckley

Market Cap: US$1.8b

A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.